Last updated: 2026-09-16 11:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Ovid Therapeutics Inc. (OVID) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.71, with a market capitalisation of $535.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.12 to $3.11. This page covers its latest market performance, valuation, price trends and company information.
$535.12M | |
$2.71 | |
$15.93 | |
$0.24 | |
$2.71 | |
-- | |
2.21M | |
-- | |
$3.11 | |
$1.12 | |
-- | |
-- |
Ovid Therapeutics Inc. (OVID) is trading at $2.71 in pre-market trading as of 2026-09-16 08:01:00, unchanged from the previous close of $2.71
Pre-market trading shows how investors are pricing OVID before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Ovid Therapeutics Inc. (OVID) moved from $2.80 to $2.71, representing a decline of 3.21% ($0.09).
The stock traded between $2.61 and $2.83 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.17 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.1%
OVID is currently trading at $2.71, placing it 80.1% of the way from its 52-week low of $1.12 to its 52-week high of $3.11. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ovid Therapeutics Inc. (OVID) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.